|
| 36879929 | Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study. | JTO Clin Res Rep | 2023 |
| 37882324 | Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. | Endocr Relat Cancer | 2023 |
| 37673108 | Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37186595 | American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. | JAMA Oncol | 2023 |
| 37015337 | NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. | J Natl Compr Canc Netw | 2023 |
| 37429923 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. | Nat Med | 2023 |
| 34611887 | Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. | J Am Geriatr Soc | 2022 |
| 35545176 | Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36545322 | Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. | JTO Clin Res Rep | 2022 |
| 36426286 | The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. | JTO Clin Res Rep | 2022 |
| 34936470 | Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. | J Clin Oncol | 2022 |
| 33069888 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. | J Thorac Oncol | 2021 |
| 33668021 | NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. | J Natl Compr Canc Netw | 2021 |
| 34544620 | Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. | Clin Lung Cancer | 2021 |
| 34244291 | Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2021 |
| 34036220 | Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2021 |
| 34048946 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. | J Thorac Oncol | 2021 |
| 32822576 | Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. | Cell | 2020 |
| 32078391 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â¿¿Positive, Advanced Nonâ¿¿Small-Cell Lung Cancer in the KEYNOTE-010 Study. | J Clin Oncol | 2020 |
| 32997124 | Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. | JAMA Netw Open | 2020 |
| 30959120 | Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. | J Thorac Oncol | 2019 |
| 31805526 | NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. | J Natl Compr Canc Netw | 2019 |
| 30138764 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. | J Thorac Oncol | 2019 |
| 31557562 | Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. | Lung Cancer | 2019 |
| 31154919 | Five-Year Overall Survival for Patients With Advanced Nonâ¿¿Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. | J Clin Oncol | 2019 |
| 30711649 | Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. | J Thorac Oncol | 2019 |
| 31117034 | NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. | J Natl Compr Canc Netw | 2019 |
| 30885353 | Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. | Lung Cancer | 2019 |
| 30876831 | Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. | Lancet Respir Med | 2019 |
| 28645632 | Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. | Clin Lung Cancer | 2018 |
| 35135148 | ALK Testing Trends and Patterns Among Community Practices in the United States. | JCO Precis Oncol | 2018 |
| 30074526 | Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. | Pancreas | 2018 |
| 30006423 | NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. | J Natl Compr Canc Netw | 2018 |
| 30429032 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. | Lung Cancer | 2018 |
| 30323087 | NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. | J Natl Compr Canc Netw | 2018 |
| 29656744 | Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. | Lung Cancer | 2018 |
| 29600052 | A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. | J Thorac Dis | 2018 |
| 28515246 | Immunotherapies for Lung Cancer. | J Natl Compr Canc Netw | 2017 |
| 28411193 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. | Cancer Immunol Res | 2017 |
| 28404761 | Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2017 |
| 28287179 | Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. | Sci Rep | 2017 |
| 29106415 | Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. | Nat Genet | 2017 |
| 25982275 | Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation. | Oncogene | 2016 |
| 27745820 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. | Lancet Oncol | 2016 |
| 27117531 | Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. | Ann Oncol | 2016 |
| 27343980 | An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. | Cancer Lett | 2016 |
| 26009269 | A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. | Lung Cancer | 2015 |
| 26496203 | A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. | PLoS One | 2015 |
| 26222619 | Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. | JAMA Dermatol | 2015 |
| 25843712 | NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. | Cell Rep | 2015 |